# Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

> **NCT05447910** · — · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 21 (actual)

## Conditions studied

- Breast Adenocarcinoma
- Invasive Breast Carcinoma
- Resectable Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05447910
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-21
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-09-27
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** insufficient funding
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447910, "Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05447910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*